INIS (Radnostix, Inc.) enters the final days of April with an unusual short interest pattern — a near-tripling in estimated short shares over four weeks followed by an abrupt halving in a single session, against a stock drifting lower toward seven cents.
The most striking move this week is the collapse in estimated short interest. After climbing from around 1,758 shares in early April to a peak above 10,500 on April 27, the figure dropped by 43% in one session to roughly 5,971 shares on April 28. That is a very small absolute count — the stock's free-float short interest remains microscopic at just 0.001% of the float, meaning bearish structural pressure is essentially nonexistent here. The week-on-week headline percentage change (+202%) looks alarming but reflects the tiny base: we are talking about a few thousand shares, not any meaningful institutional short campaign. Borrow conditions support that reading. Cost to borrow has fallen sharply from a February high above 12% to just 0.62% — near its cheapest level in over a year. Availability is effectively unlimited at 9,999% of short interest, meaning the lending pool is wide open and no squeeze mechanics are in play.
The short score — ORTEX's composite bearish positioning signal — tells the same story. It has been largely flat in the low-to-mid 25 range all week, showing no acceleration in short conviction. The 52-week utilisation peak was 20.5%, and the current reading of 0.42% is a fraction of that. This is not a stock where the short side is making a statement.
The more substantive backdrop is the company's FY2025 results, filed March 31 and publicised in early April. Radnostix reported its second-highest annual revenue in company history, driven by growth in calibration and reference products. The earnings history offers a mixed track record: the April 17 results release was accompanied by a sharp one-day decline of roughly 20%, though the five-day move recovered partially to -5.5%. An earlier March event produced a 14% one-day gain. The stock has since given back ground, closing at $0.0701 on April 29 — down 11.3% on the week and 11.9% over the past month.
Ownership is heavily concentrated among a handful of insiders and closely affiliated parties. Kennerman Associate holds 26.8% of shares, with John McCormack at 20.8% and Independent Chairman Christopher Grosso at 12.6%. These are the last reported figures from November 2025, so they should be treated as a directional indicator rather than a current snapshot. The most recent insider trade in the data — a May 2025 buy of 140,000 shares by CEO Shahe Bagerdjian at $0.05 — is now nearly a year old. With the stock trading at $0.0701, those purchases are modestly in the money. No fresh insider activity has been reported since.
With no confirmed upcoming earnings event, no analyst coverage, and a market cap of roughly $37.5 million, the next thing to watch is whether the post-results drift stabilises near current levels or accelerates — and whether the company provides any update on the key product launches referenced in its FY2025 press release, particularly around the pending NRC licence transfer noted in the Federal Register.
See the live data behind this article on ORTEX.
Open INIS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
